News

The mean PCDP was estimated by 2 different methods to be 10.7 years and 10.1 years for open-angle glaucoma.

The treatment is a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, can possibly reduce abdominal adhesions and accelerate the return of bowel function following gastrointestinal surgery.

The BLA was supported by positive data from 54 patients with hemophilia B in the pivotal phase 3 HOPE-B trial.

Only recent hospitalization and proton pump inhibitor use was deemed an independent risk factor for C difficile infections.

Neither intervention group demonstrated any significant improvements in intensity of chronic breathlessness after taking regular, low-dose, extended-release morphine.

The post-hoc analysis suggests reliable quantification of photoreceptor loss is an essential tool to evaluate therapeutic efficacy in slowing GA progression.

An interview with Dr. Markowitz on her presentation at SDPA 2022 presentation entitled ‘Skin of Color,’ regarding differentiating skin cancer from other conditions.

All ocular treatment-emergent adverse events were intravitreal injection related and mild or moderate in severity.

The incidence of NAFLD was 263.9 cases per 100,000 person-years in the infectious mononucleosis group, compared to 164.5 cases per 100,000 person-years in individuals without it.

HBsAg-positive women with adequate gestational weight again among pre-pregnancy normal-weight women had a higher risk of gestational diabetes mellitus than HBs-Ag-negative women.

A discussion with Dr. Rosen on one of his SPDA 2022 presentations, highlighting his reason for choosing the topic and exploring vitiligo misdiagnosis.

Findings from the ongoing LIBERTY AD OLE trial show the sustained long-term effect of the biologic therapy for eczema.

A discussion with Dr. Orozco on her SDPA 2022 presentation, discussing useful resources for physicians and PAs looking to get involved in the PAs Go Beyond campaign.

Two-thirds of eyes achieved a good visual outcome of 20/40 or better after cataract surgery among individuals with T2D.

In her SDPA 2022 presentation interview, Dr. Katta explores gaps in knowledge regarding the connection between skin disease and dietary health, as well as ways to address these concerns.

For NASH or NAFLD publications, the number of publications were on a continuous upward slope throughout the study period and finally surpassed HCV studies in 2020.

In the QUSAR study, 80% of patients treated with guselkumab achieved a clinical response.

The burden of sleep disorders is high among the transgender or gender-nonconforming population and this study evaluated the role of gender-affirming therapy on that relationship.

A faster rate of visual field progression was observed among 37 glaucomatous eyes treated with anti-VEGF for nAMD compared with a control group of 4304 eyes without anti-VEGF.

Dr. Katta’s interview regarding her SDPA 2022 presentation, during which she discusses the topic of obesity, dietary health, and their relationship with skin conditions like psoriasis.

Online survey results show adults with psoriasis in specific areas may be treating and monitoring disease without clinician guidance—sometimes out of embarassment.

Long-term, real-world data show the IL-23 inhibitor benefits patient-reported measures of psychological wellbeing.

New data show adults receiving the biologic for eczema may see improvements in sleep disturbance within 4 weeks.

Post hoc analysis data from JADE REGIMEN show continuous and reduced-dose regimens provided similar efficacy and safety outcomes in the 2 age groups.

An interview with Dr. Katta on her SDPA 2022 presentation, in which she covers the topic of obesity and its relationship to skin conditions such as plaque psoriasis.

In one of his SDPA 2022 presentations, Dr. Rosen spoke on different dermatological conditions with vitiligo-like presentations.

Phase 3 data suggest the novel twice-daily drug provides favorable efficacy and consistent safety over a regular regimen in patients aged 12 years and older.

Phase 3 data suggest children aged <6 months to 5 years old have benefit in itch relief and skin clearance as soon as 1 week into systemic therapy regimens.